PLx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August
July 12 2021 - 4:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to
together as “VAZALORE”), today announced that three stock-keeping
units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug
Administration (“FDA”) approved liquid-filled aspirin capsules,
will be available in over 4,500 Walmart stores across the United
States in mid-August.
The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81
mg, 30 count; and VAZALORE 325 mg, 30 count. Walmart, one of the
largest retailers in the world, has already inserted placeholders
to reserve space on shelves and alert customers that VAZALORE is
coming soon.
“We are so excited that Walmart has committed to “Coming Soon”
shelf placeholders for the next few weeks in anticipation of the
stocking of all three SKUs of VAZALORE. With Walmart’s broad reach
and millions of customers, patients will have easy access to
VAZALORE in most of their stores nationwide,” stated Natasha
Giordano, Chief Executive Officer of PLx. “Walmart’s commitment is
a real tribute to their recognition of VAZALORE as an innovative
aspirin therapy.”
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9f2f01e3-74c4-43e8-8b79-9b13d783bd7e
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024